查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094041

全球閉環式神經刺激市場：按產品、植入部位、適應症、最終用戶和地區分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Closed-Loop Neurostimulation Market By Product, Placement, Indication, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球閉環式神經刺激市場正經歷顯著成長，這主要得益於自適應神經調控技術的快速發展、臨床療效證據的不斷累積以及神經和精神疾病患者對個人化治療日益成長的需求。預計到2025年，該市場規模將達到約12億美元，並預計在2035年成長至近60億美元。在2026年至2035年的預測期內，該市場預計將維持17.5%的複合年成長率。

市場成長的主要驅動力是自適應演算法和即時神經監測技術的進步。閉環式神經刺激系統整合了先進的感測機制、計算模型和控制演算法，能夠持續分析生理訊號，並根據患者的個別反應自動調整刺激參數。與依賴固定刺激設定、需要定期進行臨床調整的傳統設備不同，閉環式系統能夠持續最佳化治療效果。

顯著的市場趨勢

全球閉環式神經刺激市場競爭激烈，各領先企業競相開發自適應刺激系統、腦機介面（BCI）及新一代神經監測平台。Medtronic憑藉其在神經調控和植入式醫療設備技術領域的深厚專業知識，在閉環式神經刺激市場中佔主導地位。

Neuropace被公認為植入式反應性神經刺激（RNS）技術領域的領先創新者，尤其是在治療藥物難治性癲癇方面。 Synchron透過開發微創血管內腦機介面（BCI）系統，已成為神經介面領域的關鍵參與者。

精準神經科學專注於開發高頻寬皮質介面系統，旨在捕捉精細的神經活動，同時最大限度地減少組織損傷。 Blackrock Neurotech 在神經介面領域擁有悠久的歷史和豐富的經驗，並在開發先進的腦波訊號擷取技術方面累積了深厚的專業知識。

主要成長要素

即時個人化正在推動整個產業從傳統的開放回路系統轉向智慧自適應刺激平台轉變，使其成為全球封閉回路刺激市場的主要成長要素。傳統的神經刺激設備通常依賴固定的刺激參數，這些參數由臨床醫生手動編程，並根據患者的回饋定期調整。雖然這些系統已展現出臨床價值，但其有效性會受到生理變異性、疾病狀態變化、患者活動量以及治療反應差異的限制。閉環式神經刺激透過持續分析神經元回饋訊號並即時自動調整刺激強度，克服了這些局限性，從而實現更加個人化和以患者為中心的治療方案。

新機會的趨勢

人工智慧、植入式設備小型化、感測器技術以及神經訊號處理領域的持續創新等技術進步，正為全球封閉回路刺激市場創造巨大的新機會。隨著人們對個人化和自適應神經調控療法的需求日益成長，新一代技術正協助開發更精準、更智慧、更有效率的閉環式系統。這些進步正在革新傳統的神經刺激方法，使設備能夠監測生理活動、解讀複雜的神經訊號，並根據患者的即時反應自動調整刺激參數。推動市場成長的關鍵因素之一是用於神經數據分析的人工智慧（AI）和機器學習演算法的快速發展。

最佳化障礙

演算法和運算方面的限制構成了重大挑戰，可能會阻礙全球閉環式神經刺激市場的成長，尤其是在下一代系統越來越依賴即時資料處理、先進感測技術和自適應刺激演算法的情況下。儘管閉環式神經刺激能夠根據生理回饋動態調整治療方案，相比傳統的開放回路型系統具有顯著優勢，但開發可靠且高效的運算架構仍然是一項複雜的技術挑戰。這些系統必須在植入式裝置尺寸、功耗和長期可靠性等方面的嚴格限制下，持續收集、處理和解讀大量的神經和生理數據。其中一項關鍵挑戰是開發能夠處理複雜資料流並即時檢測具有臨床意義的生物標記的節能處理器。

目錄

第1章摘要整理：全球封閉回路刺激市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球封閉回路刺激市場概述

  • 產業價值鏈分析
  • 產業展望
    • 全球封閉回路（響應式/自我調整）神經刺激產業概覽
    • 即時生物標記檢測、ECAP 控制和 AI 驅動的自適應治療
    • FDA突破性途徑、擴大保險覆蓋範圍以及與BCI的整合。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：依產品分類

第4章：全球封閉回路刺激市場分析

  • 競爭對手儀表板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球封閉回路刺激市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 依產品
      • 關鍵見解
        • 反應性神經刺激療法（RNS）
        • 自適應深部腦部刺激（aDBS）
        • 封閉回路脊髓刺激療法
        • 封閉回路VNS
    • 位置
      • 關鍵見解
        • 顱內/顱內
        • 脊髓
        • 迷走神經/周邊迷走神經/周圍
    • 適應症
      • 關鍵見解
        • 癲癇
        • 帕金森氏症和運動障礙
        • 慢性疼痛
        • 憂鬱症/精神疾病
    • 最終用戶
      • 關鍵見解
        • 醫院
        • 神經科和專科醫療中心
        • 門診手術中心
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

  • Medtronic（Percept aDBS）
  • NeuroPace（RNS）
  • Boston Scientific
  • Abbott
  • Saluda Medical（Evoke CL-SCS）
  • LivaNova
  • Nevro
  • Neuralink（emerging）
  • Precision Neuroscience
  • Inbrain Neuroelectronics
  • CorTec
  • Synchron
  • Paradromics
  • Motif Neurotech
  • Flow Neuroscience
  • 其他主要公司

第12章附錄

簡介目錄
Product Code: AA07261885

The global closed-loop neurostimulation market is experiencing substantial expansion, driven by rapid advancements in adaptive neuromodulation technologies, increasing clinical validation, and growing demand for personalized treatment approaches across neurological and psychiatric disorders. The market is estimated to reach approximately USD 1.2 billion in 2025 and is projected to expand to nearly USD 6.0 billion by 2035, registering a strong compound annual growth rate (CAGR) of 17.5% during the forecast period of 2026-2035.

A primary factor driving market growth is the advancement of adaptive algorithms and real-time neural monitoring technologies. Closed-loop neurostimulation systems integrate sophisticated sensing mechanisms, computational models, and control algorithms that continuously analyze physiological signals and automatically adjust stimulation parameters based on individual patient responses. Unlike traditional devices that rely on fixed stimulation settings requiring periodic clinical adjustments, closed-loop systems enable continuous optimization of therapy delivery.

Noteworthy Market Developments

The global closed-loop neurostimulation market is witnessing strong competition among leading medical technology companies that are advancing adaptive stimulation systems, brain-computer interfaces (BCIs), and next-generation neural monitoring platforms. Medtronic holds a leading position in the closed-loop neurostimulation market, supported by its extensive expertise in neuromodulation and implantable medical device technologies.

NeuroPace is recognized as a key innovator in implantable responsive neurostimulation (RNS) technology, particularly for the treatment of drug-resistant epilepsy. Synchron has emerged as a significant player in the neural interface space through its development of minimally invasive, endovascular brain-computer interface (BCI) systems.

Precision Neuroscience focuses on developing high-bandwidth cortical interface systems designed to capture detailed neural activity while minimizing tissue disruption. Blackrock Neurotech is a long-standing contributor to the neural interface field, with extensive experience developing advanced brain signal acquisition technologies.

Core Growth Drivers

Real-time personalization represents a major growth driver for the global closed-loop neurostimulation market, fueled by the industry-wide transition from conventional open-loop systems toward intelligent adaptive stimulation platforms. Traditional neurostimulation devices typically rely on fixed stimulation parameters that are manually programmed by clinicians and adjusted periodically based on patient feedback. While these systems have demonstrated clinical value, their effectiveness can be limited by physiological variations, changes in disease conditions, patient activity levels, and fluctuations in therapeutic response. Closed-loop neurostimulation addresses these limitations by continuously analyzing neural feedback signals and automatically modifying stimulation delivery in real time, enabling a more personalized and responsive treatment approach.

Emerging Opportunity Trends

Technological advancements represent a significant emerging opportunity trend for the global closed-loop neurostimulation market, driven by continuous innovation in artificial intelligence, implantable device miniaturization, sensor technology, and neural signal processing. As demand increases for personalized and adaptive neuromodulation therapies, next-generation technologies are enabling the development of more precise, intelligent, and efficient closed-loop systems. These advancements are transforming traditional neurostimulation approaches by allowing devices to monitor physiological activity, interpret complex neural signals, and automatically adjust stimulation parameters based on real-time patient responses. A major factor supporting market growth is the rapid evolution of artificial intelligence (AI) and machine learning algorithms for neural data analysis.

Barriers to Optimization

Algorithmic and computational limitations represent a significant challenge that may restrain the growth of the global closed-loop neurostimulation market, particularly as next-generation systems increasingly rely on real-time data processing, advanced sensing technologies, and adaptive stimulation algorithms. Although closed-loop neurostimulation offers substantial advantages over traditional open-loop systems by dynamically adjusting therapy based on physiological feedback, the development of reliable and efficient computational architectures remains a complex technical hurdle. These systems must continuously collect, process, and interpret large volumes of neural and physiological data while operating within strict limitations related to implant size, power consumption, and long-term device reliability. A major challenge lies in developing energy-efficient processors capable of handling complex data streams and detecting clinically meaningful biomarkers in real time.

Detailed Market Segmentation

By Product, Closed-loop Spinal Cord Stimulation (SCS) systems are expected to maintain a leading position in the global closed-loop neurostimulation market in 2026, supported by the rapid adoption of advanced sensing technologies and increasing demand for more precise, adaptive pain management solutions. The segment's dominance is primarily driven by the integration of ECAP (Evoked Compound Action Potential) sensing technology, which enables real-time monitoring of neural responses and allows stimulation parameters to be automatically adjusted according to changes in spinal cord activity. This advancement represents a significant evolution from traditional open-loop SCS systems, where stimulation settings typically require manual programming and periodic clinical adjustments.

By Placement, cranial and intracranial neurostimulation systems hold a leading position within the global closed-loop neurostimulation market, supported by the growing demand for highly precise therapeutic interventions for complex neurological disorders. The dominance of this segment is primarily driven by the critical requirement for localized, high-resolution stimulation capable of targeting specific neural regions with exceptional accuracy. Unlike peripheral or less invasive placement approaches, intracranial systems provide direct access to targeted brain structures, enabling clinicians to deliver personalized stimulation patterns for conditions where conventional treatments often provide limited effectiveness.

By Indication, chronic pain remains the leading commercial application segment within the global closed-loop neurostimulation market in 2026, maintaining its position as the most significant contributor to market revenue. The segment's dominance is driven by the growing prevalence of chronic pain disorders, rising demand for advanced non-pharmacological treatment options, and increasing clinical adoption of neuromodulation therapies as alternatives to long-term medication-based approaches. As healthcare systems continue to address the limitations and risks associated with opioid-based pain management, closed-loop neurostimulation has emerged as a promising technology offering personalized, adaptive, and targeted pain relief for patients with persistent and treatment-resistant conditions.

By End User, hospitals are expected to maintain their dominant position within the global closed-loop neurostimulation market in 2026, serving as the primary centers for the adoption, implantation, and management of advanced neuromodulation therapies. The leadership of hospitals is largely attributed to the highly specialized nature of closed-loop neurostimulation procedures, which require sophisticated surgical expertise, advanced diagnostic capabilities, multidisciplinary clinical teams, and comprehensive post-operative monitoring. Unlike conventional therapeutic approaches, these implantable systems involve complex procedures that demand precise anatomical targeting, real-time physiological assessment, and specialized programming, making hospital environments the preferred setting for successful treatment delivery.

Segment Breakdown

By Product

  • Responsive Neurostimulation (RNS)
  • Adaptive Deep Brain Stimulation (aDBS)
  • Closed-Loop Spinal Cord Stimulation
  • Closed-Loop VNS

By Placement

  • Cranial/ Intracranial
  • Spinal
  • Vagus/Peripheral

By Indication

  • Epilepsy
  • Parkinson's & Movement Disorders
  • Chronic Pain
  • Depression/Psychiatric

By End User

  • Hospitals
  • Neurology & Specialty Centers
  • Ambulatory Surgical Centers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America is expected to maintain a dominant position in the global closed-loop neurostimulation market in 2026, with the United States serving as the primary growth engine due to its advanced healthcare infrastructure, strong medical technology ecosystem, and rapid adoption of innovative neuromodulation solutions. The region's leadership is supported by substantial investments in healthcare innovation, extensive clinical research capabilities, and a well-established reimbursement framework that enables broader patient access to advanced therapeutic devices.
  • The United States accounts for approximately 85% of North America's regional revenue, reflecting its strong commercial position and high demand for advanced closed-loop neurostimulation technologies. This dominance is driven by a large patient population affected by chronic pain disorders, neurological conditions, and movement-related diseases that remain inadequately controlled through conventional treatment approaches. Closed-loop neurostimulation systems offer a more personalized therapeutic approach by continuously monitoring physiological signals and automatically adjusting stimulation parameters in real time.
  • A major factor reinforcing the U.S. market advantage is the supportive regulatory environment created by the U.S. Food and Drug Administration (FDA), which has increasingly encouraged innovation in advanced medical device technologies. Streamlined regulatory pathways, breakthrough device designations, and accelerated evaluation processes have supported the development and commercialization of next-generation ECAP (evoked compound action potential)-sensing devices.

Leading Market Participants

  • Medtronic (Percept aDBS)
  • NeuroPace (RNS)
  • Boston Scientific
  • Abbott
  • Saluda Medical (Evoke CL-SCS)
  • LivaNova
  • Nevro
  • Neuralink (emerging)
  • Precision Neuroscience
  • Inbrain Neuroelectronics
  • CorTec
  • Synchron
  • Paradromics
  • Motif Neurotech
  • Flow Neuroscience
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Closed-Loop Neurostimulation Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Closed-Loop Neurostimulation Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Electrode, Sensor, Battery & Biocompatible-Material Suppliers
    • 3.1.2. Implantable Pulse Generator & Lead / Interface Manufacturers
    • 3.1.3. Closed-Loop Sensing Algorithm, Biomarker & AI Software Developers
    • 3.1.4. Regulatory, Clinical Trial & Neurosurgical Implantation Partners
    • 3.1.5. End Users (Hospitals, Neurology & Specialty Centers, Ambulatory Surgical Centers)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Closed-Loop (Responsive/Adaptive) Neurostimulation Industry
    • 3.2.2. Real-Time Biomarker Sensing, ECAP Control & AI-Guided Adaptive Therapy
    • 3.2.3. FDA Breakthrough Pathways, Reimbursement Expansion & BCI Convergence
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Product

Chapter 4. Global Closed-Loop Neurostimulation Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Closed-Loop Neurostimulation Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Responsive Neurostimulation (RNS)
        • 5.2.1.1.2. Adaptive Deep Brain Stimulation (aDBS)
        • 5.2.1.1.3. Closed-Loop Spinal Cord Stimulation
        • 5.2.1.1.4. Closed-Loop VNS
    • 5.2.2. By Placement
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Cranial/ Intracranial
        • 5.2.2.1.2. Spinal
        • 5.2.2.1.3. Vagus/Peripheral
    • 5.2.3. By Indication
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Epilepsy
        • 5.2.3.1.2. Parkinson's & Movement Disorders
        • 5.2.3.1.3. Chronic Pain
        • 5.2.3.1.4. Depression/Psychiatric
    • 5.2.4. By End User
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Hospitals
        • 5.2.4.1.2. Neurology & Specialty Centers
        • 5.2.4.1.3. Ambulatory Surgical Centers
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. Australia & New Zealand
          • 5.2.5.1.3.5. South Korea
          • 5.2.5.1.3.6. ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa (MEA)
          • 5.2.5.1.4.1. Saudi Arabia
          • 5.2.5.1.4.2. South Africa
          • 5.2.5.1.4.3. UAE
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Product
      • 6.2.1.2. By Placement
      • 6.2.1.3. By Indication
      • 6.2.1.4. By End User
      • 6.2.1.5. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Product
      • 7.2.1.2. By Placement
      • 7.2.1.3. By Indication
      • 7.2.1.4. By End User
      • 7.2.1.5. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Product
      • 8.2.1.2. By Placement
      • 8.2.1.3. By Indication
      • 8.2.1.4. By End User
      • 8.2.1.5. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Product
      • 9.2.1.2. By Placement
      • 9.2.1.3. By Indication
      • 9.2.1.4. By End User
      • 9.2.1.5. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Product
      • 10.2.1.2. By Placement
      • 10.2.1.3. By Indication
      • 10.2.1.4. By End User
      • 10.2.1.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Medtronic (Percept aDBS)
  • 11.2. NeuroPace (RNS)
  • 11.3. Boston Scientific
  • 11.4. Abbott
  • 11.5. Saluda Medical (Evoke CL-SCS)
  • 11.6. LivaNova
  • 11.7. Nevro
  • 11.8. Neuralink (emerging)
  • 11.9. Precision Neuroscience
  • 11.10. Inbrain Neuroelectronics
  • 11.11. CorTec
  • 11.12. Synchron
  • 11.13. Paradromics
  • 11.14. Motif Neurotech
  • 11.15. Flow Neuroscience
  • 11.16. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators